There are currently 554 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of DF9001 in Patients With Advanced Solid Tumors
NCT05597839
Recruiting
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Solid Tumor, Adult
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
PARTNER 3 Trial - Aortic Valve-in-Valve
NCT03003299
Recruiting
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2024
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Register for Updates
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364
Recruiting
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Low Grade Fallopian Tube Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Ovarian Low Grade Serous Adenocarcinoma
Register for Updates
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
05/01/2024
Locations: University of Wisconsin, American Family Children's, Madison, Wisconsin
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Register for Updates
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
NCT01656603
Recruiting
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.
Gender:
ALL
Ages:
All
Trial Updated:
04/17/2024
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Infusion Reactions
Register for Updates
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885
Recruiting
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: UW Carbone Cancer Center, Madison, Wisconsin
Conditions: Multiple Myeloma
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
04/10/2024
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
The Validity of the Quick Renal MRI in Pediatric Kidney Disease
NCT03959163
Recruiting
The investigators propose a new imaging method for children born with congenital anomalies of the urinary tract that is a rapid, injection-, sedation-, and radiation-free alternative: the quick renal MRI. This proposal hypothesizes that the quick renal MRI has high validity compared to current radiologic standard for renal infection and scarring, the 99mTechnetium-dimercaptosuccinic acid (99mTc- DMSA) renal scan in the detection of acute renal infections and scars. If the quick renal MRI is accu... Read More
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
04/02/2024
Locations: American Family Children's Hospital, Madison, Wisconsin
Conditions: Pyelonephritis, Pyelonephritis Acute, Renal Sclerosis
Register for Updates
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT05230810
Recruiting
Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: HER2-positive Metastatic Breast Cancer
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Madison, Wisconsin
Conditions: Neoplasms
Register for Updates
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
NCT05237258
Recruiting
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/12/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Register for Updates